Meditationes sanctarum epistolarum 26

Invokaatio: Deo duce.

In quâ homo christianus rudi penicillo describitur ex Actis apostolorum cap. XI. versu 26

Invokaatio: Syn tō theō trismegistō.

Acute electrophysiologic consequences of pyridostigmine inhibition of cholinesterase in humans

The cardiovascular electrophysiologic basis for the action of pyridostigmine, an acetylcholinesterase inhibitor, has not been investigated. The objective of the present study was to determine the cardiac electrophysiologic effects of a single dose of pyridostigmine bromide in an open-label, quasi-experimental protocol. Fifteen patients who had been indicated for diagnostic cardiac electrophysiologic study underwent two studies just before and 90-120 min after the oral administration of pyridostigmine (45 mg). Pyridostigmine was well tolerated by all patients. Wenckebach nodal anterograde atrioventricular point and basic cycle were not altered by pyridostigmine. Sinus recovery time (ms) was shorter during a 500-ms cycle stimulation (pre: 326 ± 45 vs post: 235 ± 47; P = 0.003) but not during 400-ms (pre: 275 ± 28 vs post: 248 ± 32; P = 0.490) or 600-ms (pre: 252 ± 42 vs post: 179 ± 26; P = 0.080) cycle stimulation. Pyridostigmine increased the ventricular refractory period (ms) during the 400-ms cycle stimulation (pre: 238 ± 7 vs post: 245 ± 9; P = 0.028) but not during the 500-ms (pre: 248 ± 7 vs post: 253 ± 9; P = 0.150) or 600-ms (pre: 254 ± 8 vs post: 259 ± 8; P = 0.255) cycle stimulation. We conclude that pyridostigmine did not produce conduction disturbances and, indeed, increased the ventricular refractory period at higher heart rates. While the effect explains previous results showing the anti-arrhythmic action of pyridostigmine, the clinical impact on long-term outcomes requires further investigation.

Chronicon episcoporum Finlandensium 26

Painovuosi nimekkeestä.

Dissfrtatio [!] philologica ... fidem Jobi ex cap. XIX:25, 26, 27. Considerans, qvam ex decrete celeberrimi consistorii Acad. Aboens. adprobante ampliss. facult. phil. publico bonorum examini sistit mag. Matthias Hallenius, facult. theol. adjunctus & pastor in Lundå, respondente Gabriele Tålpo, Aboensi, ad diem Deo volente, XXVII Julii, anni MDCCXLI. In auditorio maximo, horis ante meridiem solitis

Invokaatio: In nomine Jesu!

Salvaged single-unit cord blood transplantation for 26 patients with hematologic malignancies not in remission

Treatments for patients with hematologic malignancies not in remission are limited, but a few clinical studies have investigated the effects of salvaged unrelated cord blood transplantation (CBT). We retrospectively studied 19 patients with acute leukemia, 5 with myelodysplastic syndrome (MDS with refractory anemia with excess blasts [RAEB]), and 2 with non-Hodgkin's lymphoma who received 1 CBT unit ≤2 loci human leukocyte antigen (HLA)-mismatched after undergoing myeloablative conditioning regimens between July 2005 and July 2014. All of them were in non-remission before transplantation. The infused total nucleated cell (TNC) dose was 4.07 (range 2.76-6.02)×107/kg and that of CD34+ stem cells was 2.08 (range 0.99-8.65)×105/kg. All patients were engrafted with neutrophils that exceeded 0.5×109/L on median day +17 (range 14-37 days) and had platelet counts of >20×109/L on median day +35 (range 17-70 days). Sixteen patients (61.5%) experienced pre-engraftment syndrome (PES), and six (23.1%) patients progressed to acute graft-versus-host disease (GVHD). The cumulative incidence rates of II-IV acute GVHD and chronic GVHD were 50% and 26.9%, respectively. After a median follow-up of 27 months (range 5-74), 14 patients survived and 3 relapsed. The estimated 2-year overall survival (OS), disease-free survival (DFS), and non-relapse mortality (NRM) rates were 50.5%, 40.3%, and 35.2%, respectively. Salvaged CBT might be a promising modality for treating hematologic malignancies, even in patients with a high leukemia burden.

Importância da avaliação bioquímica mensal na triagem de pacientes com desnutrição em hemodiálise

INTRODUÇÃO: A desnutrição é uma complicação frequente nos pacientes em hemodiálise, sendo o diagnóstico precoce importante para reduzir as taxas de morbidade e mortalidade do tratamento. OBJETIVO: Investigar a utilidade dos exames bioquímicos mensais realizados na hemodiálise para triagem de pacientes com desnutrição. MÉTODOS: O diagnóstico nutricional de 252 pacientes foi feito através da avaliação objetiva e subjetiva global, classificando-os em desnutridos e não desnutridos. Paralelamente, durante 4 meses consecutivos, as concentrates de creatinina, fósforo, ureia pré-e pósdiálise e o Kt/V foram registradas para cálculo das médias. Após análise dessas variáveis através da curva ROC, calculouse a sensibilidade e a especificidade na identificação dos pacientes com desnutrição. RESULTADOS: Na curva ROC, a área sob a curva para a ureia foi de 0,683, para o fósforo 0,71, para o Kt/V 0,724 e para a creatinina 0,765. Para valores de ureia < 90 mg/dL; fósforo < 4,2 mg/dL; Kt/V > 1,6 e creatinina < 6,5 mg/dL, a especificidade variou entre 80% e 88% e a sensibilidade entre 26 % e 51% . O valor preditivo negativo variou entre 90% e 92% e o valor preditivo positivo entre 23% e 32%. A associação de dois ou mais desses índices não modificou de forma significante esses valores. CONCLUSÕES: Nossos resultados sugerem que valores de ureia < 90 mg/dL, creatinina < 6,5 mg/dL, fósforo < 4,2 mg/dL e Kt/V > 1,6 podem ser utilizados para triagem de pacientes com desnutrição.